Decreased brain-expressed X-linked 4 (BEX4) expression promotes growth of oral squamous cell carcinoma

Wei Gao1, John Zeng-Hong Li1,2, Si-Qi Chen1

  • 1Department of Surgery, The University of Hong Kong, Hong Kong SAR, China.

Abstract

Insights

Brain-expressed X-linked 4 (BEX4) acts as a tumor suppressor in oral squamous cell carcinoma (OSCC). Reduced BEX4 levels promote oral cancer cell proliferation and tumor growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Brain-expressed X-linked (BEX) 4 is a member of the BEX gene family.
  • The specific role of BEX4 in oral squamous cell carcinoma (OSCC) pathogenesis was previously undefined.

Purpose of the Study:

  • To investigate the expression levels of BEX family members in OSCC.
  • To elucidate the functional role of BEX4 in OSCC proliferation and tumor growth.
  • To identify potential downstream targets and signaling pathways regulated by BEX4 in OSCC.

Main Methods:

  • Quantitative analysis of BEX1-5 expression in OSCC tissues and adjacent normal epithelia.
  • Epigenetic analysis (DNA methylation, histone modification) of BEX4 regulation using zebularine and trichostatin A (TSA) treatment in OSCC cell lines.
  • In vitro proliferation assays using real-time cell analysis (xCELLigence RTCA) and in vivo tumor growth studies in nude mice with BEX4-overexpressing OSCC cells.
  • Whole-transcriptome expression microarray analysis to identify BEX4-regulated signaling pathways.

Main Results:

  • BEX1 and BEX4 were significantly downregulated in OSCC tissues, while BEX3 was overexpressed.
  • BEX4 expression was restored in OSCC cell lines following zebularine and TSA treatment, indicating epigenetic regulation.
  • Overexpression of BEX4 suppressed OSCC cell proliferation in vitro and inhibited tumor growth in vivo.
  • Microarray analysis suggested S100A family members (S100A7, S100A7A, S100A8, S100A9, S100A12) as potential downstream targets of BEX4.

Conclusions:

  • BEX4 functions as a tumor suppressor in oral cancer by inhibiting cell proliferation and tumor growth.
  • Downregulation of BEX4 is associated with increased proliferative potential in OSCC, contributing to oral cancer development.